BIOGEN INC. Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest (Deprecated 2013-01-31)
BIOGEN INC. (BIIB) reported Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest (Deprecated 2013-01-31) of $73.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-05.
Discontinued › Notes
us-gaap:MinorityInterestIncreaseFromStockIssuance · last filed 2013-02-05
- BIOGEN INC. noncontrolling interest, increase from equity issuance or sale of parent equity interest (deprecated 2013-01-31) for fiscal 2012 was $73.00K.
- BIOGEN INC. noncontrolling interest, increase from equity issuance or sale of parent equity interest (deprecated 2013-01-31) for fiscal 2010 was $2.49M, a 65.39% decline from fiscal 2009.
- BIOGEN INC. noncontrolling interest, increase from equity issuance or sale of parent equity interest (deprecated 2013-01-31) for fiscal 2009 was $7.19M, a 47.78% increase from fiscal 2008.
- BIOGEN INC. noncontrolling interest, increase from equity issuance or sale of parent equity interest (deprecated 2013-01-31) for fiscal 2008 was $4.86M, a 158.59% increase from fiscal 2007.
| Period end | Noncontrolling Interest, Increase from Equity Issuance or Sale of Parent Equity Interest (Deprecated 2013-01-31) 12 month |
|---|---|
| 2012-12-31 | $73.00K 10-K · filed 2013-02-05 |
| 2010-12-31 | $2.49M 10-K · filed 2013-02-05 |
| 2009-12-31 | $7.19M 10-K · filed 2012-02-03 |
| 2008-12-31 | $4.86M 10-K · filed 2011-02-04 |
| 2007-12-31 | $1.88M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |